Related references
Note: Only part of the references are listed.Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Erica B. Esrick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
H. Frangoul et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice
Adam C. Wilkinson et al.
NATURE COMMUNICATIONS (2021)
Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements
Richard A. Morgan et al.
MOLECULAR THERAPY (2020)
Are genetic approaches still needed to cure sickle cell disease?
Robert A. Brodsky et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion
Shin-Young Park et al.
BLOOD (2020)
Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs
Emmanuelle Six et al.
BLOOD (2020)
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor
Naoya Uchida et al.
HAEMATOLOGICA (2020)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Gene therapy for severe combined immunodeficiencies and beyond
Alain Fischer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
The promise and challenge of therapeutic genome editing
Jennifer A. Doudna
NATURE (2020)
Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors
Jordan L. Doman et al.
NATURE BIOTECHNOLOGY (2020)
Continuous evolution of SpCas9 variants compatible with non-G PAMs
Shannon M. Miller et al.
NATURE BIOTECHNOLOGY (2020)
Expanding the genome-targeting scope and the site selectivity of high-precision base editors
Junjie Tan et al.
NATURE COMMUNICATIONS (2020)
Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype
Leslie Weber et al.
SCIENCE ADVANCES (2020)
Development of gene editing strategies for human β-globin (HBB) gene mutations
Batuhan Mert Kalkan et al.
GENE (2020)
Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy
Yoonjeong Jang et al.
GENE THERAPY (2020)
Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair
Beeke Wienert et al.
NATURE COMMUNICATIONS (2020)
Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity
Yi Yu et al.
NATURE COMMUNICATIONS (2020)
Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Oana M. Enache et al.
NATURE GENETICS (2020)
Therapeutic base editing of human hematopoietic stem cells
Jing Zeng et al.
NATURE MEDICINE (2020)
A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects
Erwei Zuo et al.
NATURE METHODS (2020)
Direct Quantification of Single Red Blood Cell Hemoglobin Concentration with Multiphoton Microscopy
Andrew T. Francis et al.
ANALYTICAL CHEMISTRY (2020)
Motivations and Decision-Making of Adult Sickle Cell Patients in High-Risk Clinical Research
Hae Lin Cho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy
Christian Brendel et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
beta T87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells
Selami Demirci et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Creating New beta-Globin-Expressing Lentiviral Vectors by High-Resolution Mapping of Locus Control Region Enhancer Sequences
Richard A. Morgan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome- and transcriptome-wide off-target effects
Sangsin Lee et al.
SCIENCE ADVANCES (2020)
Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Muhammad Naeem et al.
CELLS (2020)
AcrIIA5 Suppresses Base Editors and Reduces Their Off-Target Effects
Mingming Liang et al.
CELLS (2020)
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
Matthew M. Hsieh et al.
BLOOD ADVANCES (2020)
Rationally Designed APOBEC3B Cytosine Base Editors with Improved Specificity
Shuai Jin et al.
MOLECULAR CELL (2020)
Current Status and Challenges of DNA Base Editing Tools
You Kyeong Jeong et al.
MOLECULAR THERAPY (2020)
Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors
Andrew V. Anzalone et al.
NATURE BIOTECHNOLOGY (2020)
Characterization of red blood cell microcirculatory parameters using a bioimpedance microfluidic device
Tieying Xu et al.
SCIENTIFIC REPORTS (2020)
Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks
Han Yang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Unbiased investigation of specificities of prime editing systems in human cells
Do Yon Kim et al.
NUCLEIC ACIDS RESEARCH (2020)
Prime editing for functional repair in patient-derived disease models
Imre F. Schene et al.
NATURE COMMUNICATIONS (2020)
CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs
Matthew A. Coelho et al.
NATURE COMMUNICATIONS (2020)
Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells
Jiyung J. Shin et al.
CELL REPORTS (2020)
Allele-Specific Chromosome Removal after Cas9 Cleavage in Human Embryos
Michael Zuccaro et al.
CELL (2020)
The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing
Josu de la Fuente et al.
Lancet Haematology (2020)
Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+Hematopoietic Stem and Progenitor Cells
Haydar Frangoul et al.
BLOOD (2020)
Base Editing Eliminates the Sickle Cell Mutation and Pathology in Hematopoietic Stem Cells Derived Erythroid Cells
Jonathan S. Yen et al.
BLOOD (2020)
Adenine Base Editing of the Sickle Allele in CD34+ Hematopoietic Stem and Progenitor Cells Eliminates Hemoglobin S
S. Haihua Chu et al.
BLOOD (2020)
Adenosine Base Editing of γ-Globin Promoters Induces Fetal Hemoglobin and Inhibit Erythroid Sickling
Thiyagaraj Mayuranathan et al.
BLOOD (2020)
Single-cell mutation analysis of clonal evolution in myeloid malignancies
Linde A. Miles et al.
NATURE (2020)
Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases
Daesik Kim et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning
Rajni Agarwal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Genome-wide target specificity of CRISPR RNA-guided adenine base editors
Daesik Kim et al.
NATURE BIOTECHNOLOGY (2019)
Highly efficient therapeutic gene editing of human hematopoietic stem cells
Yuxuan Wu et al.
NATURE MEDICINE (2019)
Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation
Zhanzhuo Li et al.
NATURE COMMUNICATIONS (2019)
Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation
Agnieszka Czechowicz et al.
NATURE COMMUNICATIONS (2019)
Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque
Diego A. Espinoza et al.
MOLECULAR THERAPY (2019)
Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates
Zulema Romero et al.
MOLECULAR THERAPY (2019)
Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors
Julian Grunewald et al.
NATURE (2019)
The next generation of CRISPR-Cas technologies and applications
Adrian Pickar-Oliver et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial
Javier Bolanos-Meade et al.
LANCET HAEMATOLOGY (2019)
Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis
Changyang Zhou et al.
NATURE (2019)
Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease
So Hyun Park et al.
NUCLEIC ACIDS RESEARCH (2019)
Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates
Olivier Humbert et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
PGE2 and Poloxamer Synperonic F108 Enhance Transduction of Human HSPCs with a β-Globin Lentiviral Vector
Katelyn E. Masiuk et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes
Stosh Ozog et al.
BLOOD (2019)
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Elisa Magrin et al.
BLOOD (2019)
Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors
Chang Li et al.
MOLECULAR THERAPY (2019)
In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods
Sowmya Pattabhi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study
Mary Eapen et al.
LANCET HAEMATOLOGY (2019)
Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application
Juliane W. Schott et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats
Brent A. Williams et al.
JOURNAL OF CLINICAL MEDICINE (2019)
An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
Kristopher D. Marjon et al.
BLOOD (2019)
Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia
Angela R. Smith et al.
BLOOD (2019)
Off-target effects of cytidine base editor and adenine base editor: What can we do?
Puping Liang et al.
JOURNAL OF GENETICS AND GENOMICS (2019)
Search-and-replace genome editing without double-strand breaks or donor DNA
Andrew V. Anzalone et al.
NATURE (2019)
High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension
Giuseppe Di Caprio et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Gates and NIH join forces on HIV and sickle cell diseases
Jon Cohen et al.
SCIENCE (2019)
Emerging Genetic Therapy for Sickle Cell Disease
Stuart H. Orkin et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative
Josu de la Fuente et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
Luigi Naldini
EMBO MOLECULAR MEDICINE (2019)
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
Julie Kanter et al.
BLOOD (2019)
Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency
Rajni Agarwal et al.
BLOOD (2019)
A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates
John F. Tisdale et al.
BLOOD (2019)
Gene therapy for blood diseases
Donald B. Kohn
CURRENT OPINION IN BIOTECHNOLOGY (2019)
In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia
Hongjie Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements
Annalisa Lattanzi et al.
MOLECULAR THERAPY (2019)
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia
Sarah Marktel et al.
NATURE MEDICINE (2019)
Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins
Philippe E. Mangeot et al.
NATURE COMMUNICATIONS (2019)
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Puping Liang et al.
NATURE COMMUNICATIONS (2019)
Single-cell modeling of routine clinical blood tests reveals transient dynamics of human response to blood loss
Anwesha Chaudhury et al.
ELIFE (2019)
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
Jean-Yves Metais et al.
BLOOD ADVANCES (2019)
Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice
Chunyan Gao et al.
BLOOD ADVANCES (2019)
A microfluidic platform for simultaneous quantification of oxygen-dependent viscosity and shear thinning in sickle cell blood
Jose M. Valdez et al.
APL BIOENGINEERING (2019)
The Role of the Health Care Provider in Building Trust Between Patients and Precision Medicine Research Programs
Anitra Persaud et al.
AMERICAN JOURNAL OF BIOETHICS (2018)
Beyond Consent: Building Trusting Relationships With Diverse Populations in Precision Medicine Research
Stephanie A. Kraft et al.
AMERICAN JOURNAL OF BIOETHICS (2018)
Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives
Kirshma Khemani et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors
Graham R. Serjeant et al.
BLOOD CELLS MOLECULES AND DISEASES (2018)
UDiTaS™, a genome editing detection method for indels and genome rearrangements
Georgia Giannoukos et al.
BMC GENOMICS (2018)
Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell
Jonathan Hoggatt et al.
CELL (2018)
Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch
Nan Liu et al.
CELL (2018)
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results
Farid Boulad et al.
HAEMATOLOGICA (2018)
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
Chantal Lagresle-Peyrou et al.
HAEMATOLOGICA (2018)
Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements
Michael Kosicki et al.
NATURE BIOTECHNOLOGY (2018)
Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding
Gabriella E. Martyn et al.
NATURE GENETICS (2018)
p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells
Robert J. Ihry et al.
NATURE MEDICINE (2018)
CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response
Emma Haapaniemi et al.
NATURE MEDICINE (2018)
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
A. A. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results
Farid Boulad et al.
HAEMATOLOGICA (2018)
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
Chantal Lagresle-Peyrou et al.
HAEMATOLOGICA (2018)
Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting
Carsten T. Charlesworth et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Sickle cell disease
Gregory J. Kato et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans
Serena Scala et al.
NATURE MEDICINE (2018)
A limited number of double-strand DNA breaks is sufficient to delay cell cycle progression
Jeroen van den Berg et al.
NUCLEIC ACIDS RESEARCH (2018)
Wake-up Sleepy Gene: Reactivating Fetal Globin for beta-Hemoglobinopathies
Beeke Wienert et al.
TRENDS IN GENETICS (2018)
Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling beta AS3 Globin for Gene Therapy for Sickle Cell Disease
Valentina Poletti et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients
Erica B. Esrick et al.
BLOOD ADVANCES (2018)
Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study
John F. Tisdale et al.
BLOOD (2018)
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
Julie Kanter et al.
BLOOD (2018)
Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype
Punam Malik et al.
BLOOD (2018)
Human hemoglobin G-Makassar variant masquerading as sickle cell anemia
Ahmad Sabry Mohamad et al.
HEMATOLOGY REPORTS (2018)
Illuminating the genome-wide activity of genome editors for safe and effective therapeutics
Yong Cheng et al.
GENOME BIOLOGY (2018)
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation
Eliane Gluckman et al.
BLOOD (2017)
New agents in HSC mobilization
Meanie Domingues et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial
Darja Karpova et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem Cells
Katelyn E. Masiuk et al.
MOLECULAR THERAPY (2017)
Genome-wide target specificities of CRISPR RNA-guided programmable deaminases
Daesik Kim et al.
NATURE BIOTECHNOLOGY (2017)
Gene Therapy in a Patient with Sickle Cell Disease
Jean-Antoine Ribeil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sickle Cell Disease
Frederic B. Piel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients
Naoya Uchida et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2017)
Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing inBone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells
Kai-Hsin Chang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
Nitya Bakshi et al.
PLOS ONE (2017)
Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease
David Calvet et al.
BLOOD ADVANCES (2017)
Increased risk of leukemia among sickle cell disease patients in California
Ann Brunson et al.
BLOOD (2017)
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Michal Abraham et al.
CLINICAL CANCER RESEARCH (2017)
Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents
Alawi H. Habara et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT
Courtney D. Fitzhugh et al.
BLOOD (2017)
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial
Allistair Abraham et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease
Heather Strong et al.
ADVANCES IN THERAPY (2017)
Therapy-related myeloid neoplasms: when genetics and environment collide
Megan E. McNerney et al.
NATURE REVIEWS CANCER (2017)
Treating sickle cell disease by targeting HbS polymerization
William A. Eaton et al.
BLOOD (2017)
Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT
Courtney D. Fitzhugh et al.
BLOOD ADVANCES (2017)
Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease
Veronica van der Land et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease
Philipp M. Altrock et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Mistrust of Pediatric Sickle Cell Disease Clinical Trials Research
Evelyn M. Stevens et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2016)
Clinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study
Julie Sommet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype
Christian Brendel et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies
Guillaume Lettre et al.
LANCET (2016)
Enhancer Regulation of Transcriptional Bursting Parameters Revealed by Forced Chromatin Looping
Caroline R. Bartman et al.
MOLECULAR CELL (2016)
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Daniel P. Dever et al.
NATURE (2016)
Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin
Rahul Palchaudhuri et al.
NATURE BIOTECHNOLOGY (2016)
A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition
Elizabeth A. Traxler et al.
NATURE MEDICINE (2016)
Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases
Shengdar Q. Tsai et al.
NATURE REVIEWS GENETICS (2016)
Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin
Takeshi Masuda et al.
SCIENCE (2016)
Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy
Akanksha Chhabra et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells
Mark A. DeWitt et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
Megan D. Hoban et al.
BLOOD (2015)
211Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy
Christopher R. Burtner et al.
HUMAN GENE THERAPY (2015)
miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction
Swaroopa Guda et al.
MOLECULAR THERAPY (2015)
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Matthew C. Canver et al.
NATURE (2015)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Raya Mawad et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Fetal hemoglobin in sickle cell anemia: a glass half full?
Martin H. Steinberg et al.
BLOOD (2014)
The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Amnon Peled et al.
CLINICAL CANCER RESEARCH (2014)
Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in a Case of Severe Anemia (Reprinted from Arch Intern Med (Chic)., vol 6, pg 517-521, 1910)
James B. Herrick
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members
Barbara P. Yawn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Radioimmunotherapy for hematopoietic cell transplantation
Joseph G. Jurcic
IMMUNOTHERAPY (2013)
Genetic modifiers of sickle cell disease
Martin H. Steinberg et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure
Michael R. DeBaun et al.
BLOOD (2012)
Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin
Duyen A. Ngo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease
Marco Andreani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age
Wendy W. Pang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Marina Cavazzana-Calvo et al.
NATURE (2010)
Busulfan in Hematopoietic Stem Cell Transplantation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?
Courtney D. Fitzhugh et al.
CYTOTHERAPY (2009)
The β-globin nuclear compartment in development and erythroid differentiation
RJ Palstra et al.
NATURE GENETICS (2003)
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
JM Burke et al.
BONE MARROW TRANSPLANTATION (2003)
Hb G-Makassar [beta 6(A3)Glu -> Ala; codon 6 (GAG -> GCG)]: Molecular characterization, clinical, and hematological effects
V Viprakasit et al.
HEMOGLOBIN (2002)
Malevolent Ogbanje:: recurrent reincarnation or sickle cell disease?
E Nzewi
SOCIAL SCIENCE & MEDICINE (2001)
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
MC Walters et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Share Paper
